Sutro Biopharma (STRO) Expected to Post Earnings on Thursday

Key Points

• Sutro Biopharma is expected to report Q3 2026 results before market open on November 5. Analysts forecast a loss of $1.66 per share and revenue of $13.61 million; the conference call is scheduled for November 6 at 9:30 a.m. ET.
• The company missed expectations in its previous quarter, reporting a $2.33 per-share loss and $9.84 million in revenue versus estimates of a $2.19 loss and $11.96 million in revenue.
• Shares have declined sharply, opening at $9.29 versus 50-day and 200-day moving averages of $15.88 and $22.80. Despite the weakness, analysts maintain a consensus “Buy” rating with an average price target of $49.50.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) will likely be announcing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Sutro Biopharma to post earnings of ($1.6637) per share and revenue of $13.61 million for the quarter. Investors can find conference call details on the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 6, 2026 at 9:30 AM ET.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($2.33) EPS for the quarter, missing the consensus estimate of ($2.19) by ($0.14). The business had revenue of $9.84 million for the quarter, compared to analysts' expectations of $11.96 million. On average, analysts expect Sutro Biopharma to post ($8.41) EPS for the current fiscal year and ($6.95) EPS for the next fiscal year.

Sutro Biopharma Stock Performance

STRO opened at $9.29 on Thursday. The firm's fifty day moving average is $15.88 and its two-hundred day moving average is $22.80. The firm has a market cap of $154.03 million, a PE ratio of -0.78 and a beta of 1.49. Sutro Biopharma has a twelve month low of $7.15 and a twelve month high of $43.85.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Wedbush restated an "outperform" rating and issued a $60.00 price objective on shares of Sutro Biopharma in a research report on Thursday, October 15th. Wells Fargo & Company began coverage on Sutro Biopharma in a research note on Wednesday, September 30th. They set an "overweight" rating and a $49.00 price objective on the stock. Citizens Jmp reduced their target price on Sutro Biopharma from $41.00 to $34.00 and set a "market outperform" rating on the stock in a report on Thursday, August 13th. Weiss Ratings cut Sutro Biopharma from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Monday, October 19th. Finally, Citigroup reissued a "market outperform" rating on shares of Sutro Biopharma in a research note on Thursday, August 13th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Sutro Biopharma currently has an average rating of "Buy" and an average target price of $49.50.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biotechnology company focused on developing medicines for cancer and other serious diseases. The company uses its proprietary XpressCF cell-free protein synthesis platform to design and manufacture targeted biologic therapies, including antibody-drug conjugates (ADCs) and cancer immunotherapies.

Sutro's research programs have included luveltamab tazevibulin, also known as STRO-002, a folate receptor alpha-targeted ADC being investigated for ovarian and endometrial cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.